Pharmacodynamic analysis of a serine protease inhibitor, MK-4519, against hepatitis C virus using a novel In Vitro pharmacodynamic system

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 3, 2012, Pages 1170-1181

  Brown, Ashley N ^a   McSharry, James J ^a   Adams, Jonathan R ^a   Kulawy, Robert ^a   Barnard, Richard J O ^b   Newhard, W ^b   Corbin, A ^b   Hazuda, Daria J ^b   Louie, Arnold ^a   Drusano, George L ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; MK 4519; SERINE PROTEINASE INHIBITOR; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ARTICLE; CONTROLLED STUDY; DOSE CALCULATION; DOSE RESPONSE; HEPATITIS C; IN VITRO STUDY; NONHUMAN; OPTIMAL DRUG DOSE; PHARMACODYNAMICS; PRIORITY JOURNAL; REPLICON; VIRUS INHIBITION; VIRUS MUTATION; VIRUS REPLICATION;

ANTIVIRAL AGENTS; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DOSAGE CALCULATIONS; DRUG RESISTANCE, VIRAL; GENES, REPORTER; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INHIBITORY CONCENTRATION 50; LUCIFERASES; MODELS, BIOLOGICAL; MUTATION; REPLICON; RNA, VIRAL; SERINE PROTEASES; SERINE PROTEINASE INHIBITORS; VIRAL NONSTRUCTURAL PROTEINS; VIRUS REPLICATION;

EID: 84857176866     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.05383-11     Document Type: Article

References (29)

1. Adiwijaya BS, et al. 2010. A multi-variant, viral dynamic model of genotype 1 HCV to assess the in vivo evolution of protease-inhibitor resistant variants. PLoS Comput. Biol. 6:e1000745.
2. Brown AN, et al. 2011. Effect of half-life on the pharmacodynamic index of zanamivir against influenza virus delineated by a mathematical model. Antimicrob. Agents Chemother. 55:1747-1753.
3. Brown AN, et al. 2011. Zanamivir, at 600 milligrams twice daily, inhibits oseltamivir-resistant 2009 pandemic H1N1 influenza virus in an in vitro hollow-fiber infection model system. Antimicrob. Agents Chemother. 55:1740-1746.
4. Brown AN, et al. 2010. In vitro system for modeling influenza A virus resistance under drug pressure. Antimicrob. Agents Chemother. 54:3442-3450.
5. Drusano GL, et al. 2001. Hollow-fiber unit evaluation of a new human immunodeficiency virus type 1 protease inhibitor, BMS-232632, for determination of the linked pharmacodynamic variable. J. Infect. Dis. 183:1126-1129. (Pubitemid 32230964)
6. Drusano GL, et al. 2002. Pharmacodynamics of abacavir in an in vitro hollow-fiber model system. Antimicrob. Agents Chemother. 46:464-470. (Pubitemid 34087197)
7. Ghany MG, Strader DB, Thomas DL, Seeff LB. 2009. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 49:1335-1374.
8. Ho L, Greene CL, Schmidt AW, Huang LH. 2004. Cultivation of HEK 293 cell line and production of a member of the superfamily of G-protein coupled receptors for drug discovery applications using a highly efficient novel bioreactor. Cytotechnology 45:117-123. (Pubitemid 40569216)
9. Klumpp K, et al. 2006. The novel nucleoside analog R1479 (4′-azidocytidine) is a potent inhibitor of NS5B-dependent RNA synthesis and hepatitis C virus replication in cell culture. J. Biol. Chem. 281:3793-3799. (Pubitemid 43847803)
10. Kuntzen T, et al. 2008. Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naive patients. Hepatology 48:1769-1778.
11. Lin C, et al. 2004. In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: structural analysis indicates different resistance mechanisms. J. Biol. Chem. 279:17508-17514. (Pubitemid 38560514)
12. Lin K, Perni RB, Kwong AD, Lin C. 2006. VX-950, a novel hepatitis C virus (HCV) NS3-4A protease inhibitor, exhibits potent antiviral activities in HCV replicon cells. Antimicrob. Agents Chemother. 50:1813-1822.
13. Liverton NJ, et al. 2008. Molecular modeling based approach to potent P2-P4 macrocyclic inhibitors of hepatitis C NS3/4A protease. J. Am. Chem. Soc. 130:4607-4609. (Pubitemid 351500096)
14. Lopez-Labrador FX, Moya A, Gonzalez-Candelas F. 2008. Mapping natural polymorphisms of hepatitis C virus NS3/4A protease and antiviral resistance to inhibitors in worldwide isolates. Antivir. Ther. 13:481-494. (Pubitemid 352016711)
15. McSharry JJ, Deziel MR, Zager K, Weng Q, Drusano GL. 2009. Pharmacodynamics of cidofovir for vaccinia virus infection in an in vitro hollow-fiber infection model system. Antimicrob. Agents Chemother. 53:129-135.
16. McSharry JJ, Weng Q, Brown A, Kulawy R, Drusano GL. 2009. Prediction of the pharmacodynamically linked variable of oseltamivir carboxylate for influenza A virus using an in vitro hollow-fiber infection model system. Antimicrob. Agents Chemother. 53:2375-2381.
17. Merck & Co. Inc. 13 May 2011. FDA approves Merck's VICTRELIS™(boceprevir), first-in-class oral hepatitisCvirus (HCV) protease inhibitor. Merck & Co. Inc., Whitehouse Station, NJ.
18. Merck & Co Inc. 2011. VICTRELIS (boceprevir) prescribing information. Merck & Co. Inc., Whitehouse Station, NJ.
19. Reesink HW, et al. 2010. Rapid HCV-RNA decline with once daily TMC435: a phase I study in healthy volunteers and hepatitis C patients. Gastroenterology 138:913-921.
20. Sarrazin C, et al. 2007. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 132:1767-1777. (Pubitemid 46677938)
21. Thompson AJ, McHutchison JG. 2009. Antiviral resistance and specifically targeted therapy for HCV (STAT-C). J. Viral Hepat. 16:377-387.
22. Toriniwa H, Komiya T. 2007. Japanese encephalitis virus production in Vero cells with serum-free medium using a novel oscillating bioreactor. Biologicals 35:221-226. (Pubitemid 47562780)
23. Vertex Pharmaceuticals Inc. 27 May 2011. FDA advisory committee unanimously recommends approval of telaprevir for people with hepatitis C. Vertex Pharmaceuticals Inc., Cambridge, MA.
24. Vertex Pharmaceuticals Inc. 2011. INCIVEK (telaprevir) prescribing information. Vertex Pharmaceuticals Inc., Cambridge, MA.
25. Welsch C, et al. 2008. Molecular basis of telaprevir resistance due to V36 and T54 mutations in the NS3-4A protease of the hepatitis C virus. Genome Biol. 9:R16.
26. White PW, et al. 2010. Preclinical characterization of BI 201335, a C-terminal carboxylic acid inhibitor of the hepatitis C virus NS3-NS4A protease. Antimicrob. Agents Chemother. 54:4611-4618.
27. Yi M, Villanueva RA, Thomas DL, Wakita T, Lemon SM. 2006. Production of infectious genotype 1a hepatitis C virus (Hutchinson strain) in cultured human hepatoma cells. Proc. Natl. Acad. Sci. U. S. A. 103:2310-2315. (Pubitemid 43271666)
28. Zhou Y, et al. 2008. Phenotypic characterization of resistant Val36 variants of hepatitis C virus NS3-4A serine protease. Antimicrob. Agents Chemother. 52:110-120.
29. Zhou Y, et al. 2007. Phenotypic and structural analyses of hepatitis C virus NS3 protease Arg155 variants: sensitivity to telaprevir (VX-950) and interferon alpha. J. Biol. Chem. 282:22619-22628. (Pubitemid 47267330)